Evoke Pharma and EVERSANA Expand GIMOTI庐 Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
Evoke Pharma (NASDAQ: EVOK) has announced significant expansion of access to its GIMOTI庐 nasal spray through new strategic partnerships. The company has secured relationships with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy, which will substantially increase GIMOTI's availability through specialty pharmacy networks.
The Omnicell partnership will facilitate GIMOTI distribution to major gastroenterology organizations, including Gastro Health (150 locations across 7 states) and OneGI (200+ gastroenterologists across multiple states). These partnerships are expected to nearly double the number of specialty pharmacies with access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis.
Evoke Pharma (NASDAQ: EVOK) ha annunciato un'importante estensione dell'accesso al suo spray nasale GIMOTI庐 grazie a nuove partnership strategiche. L'azienda ha siglato accordi con Omnicell (NASDAQ: OMCL) e Brentwood Pharmacy, che aumenteranno notevolmente la disponibilit脿 di GIMOTI all'interno delle reti di farmacie specializzate.
La collaborazione con Omnicell agevoler脿 la distribuzione di GIMOTI verso grandi organizzazioni di gastroenterologia, tra cui Gastro Health (150 sedi in 7 stati) e OneGI (oltre 200 gastroenterologi in diversi stati). Queste alleanze dovrebbero quasi raddoppiare il numero di farmacie specialistiche che potranno fornire GIMOTI, l'unico spray nasale approvato dalla FDA per adulti con gastroparesi diabetica acuta e ricorrente.
Evoke Pharma (NASDAQ: EVOK) ha anunciado una importante ampliaci贸n del acceso a su spray nasal GIMOTI庐 mediante nuevas alianzas estrat茅gicas. La compa帽铆a ha establecido relaciones con Omnicell (NASDAQ: OMCL) y Brentwood Pharmacy, lo que incrementar谩 sustancialmente la disponibilidad de GIMOTI en las redes de farmacias especializadas.
La asociaci贸n con Omnicell facilitar谩 la distribuci贸n de GIMOTI a grandes organizaciones de gastroenterolog铆a, incluidas Gastro Health (150 ubicaciones en 7 estados) y OneGI (m谩s de 200 gastroenter贸logos en varios estados). Se espera que estas colaboraciones casi dupliquen el n煤mero de farmacias especializadas con acceso a GIMOTI, el 煤nico spray nasal aprobado por la FDA para adultos con gastroparesia diab茅tica aguda y recurrente.
Evoke Pharma (NASDAQ: EVOK)電� 靸堧鞖� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 韱淀暣 鞛愳偓 GIMOTI庐 牍勱皶 鞀ろ攧霠堨澊鞐� 雽�頃� 鞝戧芳靹膘潉 韥矊 頇曤寑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� Omnicell (NASDAQ: OMCL)瓿� Brentwood Pharmacy鞕�鞚� 甏�瓿勲ゼ 頇曤炒頃橃棳 鞝勲 鞎疥淡 雱ろ姼鞗岉伂毳� 韱淀暅 GIMOTI鞚� 瓿店笁鞚� 韥矊 電橂Υ 鞓堨爼鞛呺媹雼�.
Omnicell瓿检潣 韺岉姼雱堨嫮鞚� Gastro Health(7臧� 欤检棎 瓯胳硱 150臧� 歆�鞝�) 氚� OneGI(鞐煬 欤检棎 瓯胳硱 200氇� 鞚挫儊鞚� 鞙勳灔氤� 鞝勲鞚�)毳� 韽暔頃� 欤检殧 鞙勳灔氤戫暀 旮瓣磤鞙茧鞚� GIMOTI 鞙犿喌鞚� 鞖╈澊頃橁矊 頃� 瓴冹瀰雼堧嫟. 鞚措煬頃� 鞝滍湸搿� GIMOTI鞐� 鞝戧芳頃� 靾� 鞛堧姅 鞝勲 鞎疥淡 靾橁皜 瓯办潣 霊� 氚�搿� 電橃柎雮� 瓴冹溂搿� 鞓堨儊霅橂┌, GIMOTI電� 旮夓劚 氚� 鞛皽靹� 雼闺嚚氤戩劚 鞙勲牍勱皜 鞛堧姅 靹膘澑鞚� 鞙勴暅 FDA 鞀轨澑 鞙犾澕鞚� 牍勱皶 鞀ろ攧霠堨澊鞛呺媹雼�.
Evoke Pharma (NASDAQ: EVOK) a annonc茅 une expansion significative de l'acc猫s 脿 son spray nasal GIMOTI庐 gr芒ce 脿 de nouveaux partenariats strat茅giques. La soci茅t茅 a conclu des accords avec Omnicell (NASDAQ: OMCL) et Brentwood Pharmacy, ce qui augmentera sensiblement la disponibilit茅 de GIMOTI via les r茅seaux de pharmacies sp茅cialis茅es.
Le partenariat avec Omnicell facilitera la distribution de GIMOTI aux grandes organisations de gastro-ent茅rologie, notamment Gastro Health (150 sites dans 7 脡tats) et OneGI (plus de 200 gastro-ent茅rologues dans plusieurs 脡tats). Ces collaborations devraient presque doubler le nombre de pharmacies sp茅cialis茅es ayant acc猫s 脿 GIMOTI, le seul spray nasal approuv茅 par la FDA pour les adultes atteints de gastroparesie diab茅tique aigu毛 et r茅currente.
Evoke Pharma (NASDAQ: EVOK) hat eine deutliche Erweiterung des Zugangs zu seinem GIMOTI庐 Nasenspray durch neue strategische Partnerschaften angek眉ndigt. Das Unternehmen hat Vereinbarungen mit Omnicell (NASDAQ: OMCL) und Brentwood Pharmacy geschlossen, die die Verf眉gbarkeit von GIMOTI in Spezialapotheken-Netzwerken erheblich erh枚hen werden.
Die Partnerschaft mit Omnicell wird die Verbreitung von GIMOTI an gro脽e gastroenterologische Einrichtungen erleichtern, darunter Gastro Health (150 Standorte in 7 Bundesstaaten) und OneGI (眉ber 200 Gastroenterologen in mehreren Bundesstaaten). Es wird erwartet, dass diese Kooperationen die Zahl der Spezialapotheken mit Zugang zu GIMOTI fast verdoppeln 鈥� GIMOTI ist das einzige von der FDA zugelassene Nasenspray f眉r Erwachsene mit akuter und wiederkehrender diabetischer Gastroparese.
- Expected to double specialty pharmacy network access for GIMOTI
- Partnership with Omnicell enables access to large gastroenterology practices like Gastro Health (150 locations)
- Agreement with Brentwood Pharmacy provides access to OneGI network (200+ gastroenterologists)
- Improved insurance plan coverage through expanded pharmacy network
- None.
Insights
Evoke Pharma's expanded pharmacy network through Omnicell and Brentwood partnerships significantly increases GIMOTI's market reach to major GI practices.
Evoke Pharma's strategic expansion of GIMOTI's distribution network represents a significant commercial advancement for their flagship product. By partnering with Omnicell, Evoke gains critical access to specialty pharmacies utilized by large gastroenterology organizations like Gastro Health, which maintains 150 locations across 7 states. This integration directly addresses a key challenge in specialty pharmaceuticals - aligning with the existing pharmacy infrastructure that physicians already trust and utilize.
The additional agreement with Brentwood Pharmacy creates a pathway to OneGI's network of approximately 200 gastroenterologists across multiple states. Together, these partnerships are positioned to nearly double GIMOTI's specialty pharmacy network, dramatically expanding the product's footprint within the gastroenterology specialty.
What makes this particularly valuable is that GIMOTI remains the only FDA-approved nasal spray for diabetic gastroparesis, giving it a unique clinical position. By reducing access barriers through these pharmacy relationships, Evoke is addressing a fundamental commercialization challenge in specialty pharmaceuticals - ensuring that innovative medications can efficiently reach the physicians who prescribe them and the patients who need them.
These distribution expansions represent execution on Evoke's publicly communicated commercial strategy, potentially accelerating GIMOTI's adoption curve by removing logistical obstacles that often impede specialty medication uptake and enhancing patient access to this novel delivery system for metoclopramide.
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement
Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships
SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.聽(NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI庐聽(metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the addition of Omnicell (NASDAQ: OMCL), a leader in medication management and fulfillment. This relationship is expected to expand patient access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis specifically, into large gastroenterology organizations.
As part of Evoke鈥檚 strategy to broaden GIMOTI鈥檚 reach through key pharmacy partnerships, the addition of Omnicell is meant to ensure better alignment with specialty pharmacies used by large gastroenterology group practices, like Gastro Health, which has a presence in 7 states and 150 locations. Omnicell manages a collection of these targeted pharmacies that specialize in GI products that are affiliated with large gastrointestinal physician organizations. This relationship is expected to almost double the number of specialty pharmacies available to access Gimoti.
鈥淎dding Omnicell as a pharmacy manager is a direct reflection of the strategy we鈥檝e shared publicly 鈥� to improve patient access by aligning with the specialty pharmacies GI physicians trust and use every day,鈥� said Matt D鈥橭nofrio, Chief Executive Officer of Evoke Pharma. 鈥淲ith support from EVERSANA and integration with Omnicell, we鈥檙e working to remove barriers for providers and help patients get the care they need faster.鈥�
鈥淟arge GI practices are structured for scale and efficiency, and many have long-standing relationships with preferred specialty pharmacies,鈥� said Chris Quesenberry, Chief Commercial Officer at Evoke Pharma. 鈥淥mnicell is an organization that understands the complexities of specialty care and offers turnkey solutions intended to optimize provider and patient experience. It鈥檚 another major step forward in making GIMOTI accessible in the real-world environments where patients are being treated.鈥�
In a separate agreement, Evoke has also accessed Brentwood Pharmacy via a partnership agreement via Eversana. Brentwood is the specialty pharmacy affiliated with OneGI, another large gastroenterology network located in Tennessee, Kentucky, Ohio, Mississippi and other surrounding states. OneGI manages approximately 200 gastroenterologists and specialized physician assistants located at over 30 offices. This expansion further enables rapid delivery of GIMOTI and expands access to additional insurance plans for patients.
About聽Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in聽the United States聽to treat gastroparesis.
痴颈蝉颈迟听聽for more information.
Follow聽Evoke Pharma聽on聽
Follow聽Evoke Pharma聽on聽
About Gimoti庐聽(metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information:
WARNING: TARDIVE DYSKINESIA
- Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
- Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
- Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.
GIMOTI is not recommended for use in:
- Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
- Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.
GIMOTI is contraindicated:
- In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
- When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).
- In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
- In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
- In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.
Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (鈮�
痴颈蝉颈迟听聽or call 1-800-FDA-1088.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渃ould,鈥� 鈥渋ntend,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渃ontemplates,鈥� 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� 鈥減otential鈥� or 鈥渃ontinue鈥� or the negatives of these terms or other similar expressions. These statements are based on the company鈥檚 current beliefs and expectations. These forward-looking statements include statements regarding: the potential expansion of access to GIMOTI through the relationships with Omnicell and Brentwood Pharmacy; and Evoke鈥檚 commercial strategy. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke鈥檚 business, including, without limitation: Evoke and EVERSANA may not be able to successfully drive market demand for GIMOTI; alternative treatments for gastroparesis may be developed or approved and may be shown to be superior to GIMOTI; Evoke鈥檚 ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; Evoke鈥檚 ability to maintain compliance with Nasdaq鈥檚 stockholder鈥檚 equity requirements; Evoke鈥檚 dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke鈥檚 ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke鈥檚 prior press releases and in the periodic reports it files with the聽Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
About EVERSANA
EVERSANA庐聽is a leading independent provider of global services to the life sciences industry. The company鈥檚 integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit聽聽or connect through聽听补苍诲听.
About Gastro Health
Gastro Health is a leading medical group made up of physicians and advanced practitioners specializing in the treatment of gastrointestinal disorders, nutrition, and digestive health.聽Gastro Health has a presence in seven states 鈥� Florida, Alabama, Washington, Virginia, Ohio, Maryland, and Massachusetts 鈥� with over 350 physicians and 150 locations consisting of medical offices, infusion centers, imaging services, and a specialty pharmacy.
About One GI庐
One GI庐 is a gastroenterology management services organization that partners with GI physicians to help them manage, optimize, and grow their practices. One GI庐 provides critical business services to physicians so they can focus on what they do best: providing excellent care to patients. For additional information on One GI庐, please visit聽.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
FAQ
What is the significance of Evoke Pharma's partnership with Omnicell for GIMOTI distribution?
How many locations will GIMOTI be available through the new Gastro Health partnership?
What is GIMOTI and what is it used for?
How many gastroenterologists are included in the OneGI network partnership?
How will these partnerships affect EVOK's specialty pharmacy network?
